REDX.L Regulatory News (REDX)

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN

REDX PHARMA PLC

("Redx" or "the Company")

Redx appoints Senior AstraZeneca Executive as new Chief Executive Officer

Alderley Park, 24 April 2018 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that it has appointed Lisa Anson as Chief Executive Officer (CEO) and to its Board of Directors. Lisa will take up both roles on 1 June 2018. At that time Iain Ross, currently Executive Chairman, will revert to being Non-Executive Chairman.

Lisa Anson, aged 49, has been President of AstraZeneca UK since 2012 and brings significant leadership experience to the role. Over a 20 year career with AstraZeneca, Lisa has held a variety of senior management roles at AstraZeneca in both the US and the UK including Global Vice President Oncology and Vice President of Emerging Brands working closely with the Research and Development teams.

Lisa holds a MBA (awarded with distinction) from INSEAD, France and a First Class honours degree in Natural Sciences from Cambridge University. Upon graduating she joined KPMG in London as a management consultant and then moved to California where she worked for Salick Health Care (now Aptium), a cancer disease management company, prior to joining Zeneca Pharmaceuticals (USA) in 1998 as a business development manager.

Lisa is the current President of the Association of the British Pharmaceutical Industry (ABPI).

Iain Ross, Executive Chairman of Redx plc, said:

"On behalf of the Board and the team, I welcome Lisa to Redx. Following the events of 2017 Lisa has been tasked by the Board to lead the re-launch of the Company and to take the steps necessary to build a substantial biotech company built upon an innovative science base, selectively acquiring additional assets, if appropriate. Lisa is a consummate business professional, who brings a wealth of relevant experience from the international pharmaceutical and biotech sector. I am confident that, as CEO, she is the right person to grow this Company into a very exciting and meaningful entity that has the potential to create both important new medicines for patients and generate significant value for shareholders."

"I would like to take this opportunity to thank the Redx team for the tremendous effort they have made over the last six months whilst the business has been in transition. Lisa's appointment marks a new beginning"

Lisa Anson, CEO designate of Redx plc, added:

"I am incredibly excited by the opportunity to lead Redx on the next stage of its journey to be a leading UK Biotech company. The team have impressed me and The Company now has a clear focus on some very exciting areas of science in both fibrosis and cancer where there are a number of ongoing programmes. I look forward to working with the team and the Board to build and develop Redx to its full potential"

Additional Information

The following information is being disclosed pursuant to Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Full name: Lisa Mary Whewell Anson

Ms Anson does not hold any shares in the Company.

Ms Anson is a director of the Association of the British Pharmaceutical Industry, the Office for Health Economics and a trustee for Wilmslow Preparatory School. Ms Anson was previously a director of Weston Sports & Media LLP and Weston Sports & Media Consulting Limited.

-Ends-

For further information, please contact:

About Redx Pharma Plc 

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.